Format

Send to

Choose Destination
Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Author information

1
Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria.
2
Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria.
3
Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria. Electronic address: r.greil@salk.at.

KEYWORDS:

Biomarker; Metastatic; Resistance; Trastuzumab; VEGF

PMID:
24246725
DOI:
10.1016/j.clbc.2013.09.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center